Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in Mild to Moderate Alzheimer's Disease
2024-511610-20-00Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing GV1001 with Placebo (2 arms). Primary endpoints: Change from baseline in ADAS-Cog11 score at Week 52 and Safety and tolerability profile. Started May 2024; status: completed.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-511610-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511610-20-00.